Literature DB >> 8575434

Amino acid residues 721-729 are required for full factor VIII activity.

M Kjalke1, A Heding, G Talbo, E Persson, J Thomsen, M Ezban.   

Abstract

Recombinant two-chain factor VIII, from which the B domain had been deleted, was expressed in Chinese hamster ovary cells. In addition to the major product, three minor factor VIII forms were isolated. The A2 domains generated by thrombin cleavage showed different electrophoretic mobilities. Peptide mapping of the A2 domains showed that two of the factor VIII forms had the expected C-terminus of the heavy chain at Arg740 [FVIII-(1-740)] and that the other factor VIII forms had C-termini at Tyr729 [FVIII-(1-729)] or Glu720 [FVIII-(1-720)]. The major FVIII-(1-740) form, FVIII-(1-729), and FVIII-(1-720) contained sulfated tyrosine residues at Tyr718, Tyr719 and Tyr723. The minor FVIII-(1-740) form was shown to lack sulfation at these positions. The specific clotting activity was approximately 1 x 10(4) U/mg for FVIII-(1-740) (both forms) and FVIII-(1-729), but twofold lower for FVIII-(1-720). A time study of thrombin activation showed that FVIII-(1-720) was activated slower than FVIII-(1-740), FVIII-(1-729) and plasma-derived factor VIII. Partially sulfated FVIII-(1-740) was activated at the same rate as the fully sulfated FVIII-(1-740). The equilibrium dissociation constant for binding of factor VIII to inactivated immobilized thrombin was the same for all factor VIII forms, showing that the slower activation of FVIII-(1-720) was not due to a lower affinity for the anion-binding exosite in thrombin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8575434     DOI: 10.1111/j.1432-1033.1995.773_a.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  3 in total

1.  Proteolytic cleavage of recombinant two-chain factor VIII during cell culture production is mediated by protease(s) from lysed cells. The use of pulse labelling directly in production medium.

Authors:  K Hansen; M Kjalke; P B Rasmussen; L Kongerslev; M Ezban
Journal:  Cytotechnology       Date:  1997-09       Impact factor: 2.058

Review 2.  Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.

Authors:  Mirella Ezban; Knud Vad; Marianne Kjalke
Journal:  Eur J Haematol       Date:  2014-05-28       Impact factor: 2.997

3.  Blood Clotting Factor VIII: From Evolution to Therapy.

Authors:  N A Orlova; S V Kovnir; I I Vorobiev; A G Gabibov; A I Vorobiev
Journal:  Acta Naturae       Date:  2013-04       Impact factor: 1.845

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.